logo-loader

Valeo Pharma’s Redesca receives positive review for public reimbursement in Quebec

Published: 10:44 26 Jan 2021 EST

Valeo Pharma (CSE: VPH- OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive with news the company has received a notice of a positive recommendation to the Quebec Ministry of Health in regards to potentially seeing public reimbursement of their low molecular weight heparin biosimilar Redesca. Saviuk talks about this milestone and also when they are expecting the Canadian launch of Redesca and Redesca HP.

Valeo Pharma Q1 numbers shows asthma product revenues increasing by 58%

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the first quarter ended January 31, 2024. Valeo Pharma reported revenues of $13.5 million in Q1-24, compared to $13.1 million in Q1-23 and $13.1 million in Q4-23, representing a 3%...

1 week, 3 days ago